Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and itsRead
Physical inactivity is a common factor in lifestyle diseases – and one that is often linked to the excessive consumption of fatty and/or sugary foods. The opposite scenario of excessive physical activity at the expense of caloric intake can also be harmful, as cases of anorexia nervosa illustrate. These scenariosRead
“The brain and the gut speak the same language” (1) Ethan Russo, MD, Renown Cannabinoid Scientist The endocannabinoid system (ECS) is a network of receptors and enzymes that are spread throughout the body. This system can interact with one’s own cannabinoids (endogenous or endocannabinoids) because of substances found in natureRead
The chemical compounds called cannabinoids, found in cannabis and hemp, are also produced naturally in the body from omega-3 fatty acids. A new study in animal tissue reveals the cascade of chemical reactions that convert omega-3 fatty acids into cannabinoids that have anti-inflammatory benefits. The findings are published in theRead
A recent New York Times article, CBD is Everywhere, But Scientists Still Don’t Know Much About It, paints a picture of snake-oil sales, hyped-up claims and minuscule science. Is that true or a journalistic stretch? The article prompted Today’s Practitioner to dig up two well-researched studies from Cannabis and CannabinoidRead
In this study, published in PLOS ONE, researchers explored the role of cannabidiol for intestinal inflammation. This research looked enteric glial cells (EGC), which plays a fundamental role in the maintenance of gut homeostasis. They assure the correct trophism of vicinal neurons in the myenteric plexus and actively participate inRead
Approximately 25 percent of drug-resistant epilepsy patients taking cannabidiol (CBD) developed a tolerance to the treatment, researchers said at the American Epilepsy Society annual meeting taking place Nov.30 – Dec. 4, 2018. The findings suggest that that the effectiveness of the CBD drug might wane in the long term forRead
Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.
